Skip to main content

Erratum to: Dual HER2 blockade: preclinical and clinical data

The Original Article was published on 31 July 2014


No abstract.


After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).

Figure 1
figure 1

Dual blockade with antibody–drug conjugate and targeted therapy. (A) SCID Beige mice were injected with 1 million cells per mouse in the estrogen receptor-positive, human epidermal growth factor receptor (HER)-positive cell line called BT474-m1. These animals were randomized into six groups and treated with: vehicle control; trastuzumab (5 mg/kg once weekly); lapatinib (100 mg/kg daily); ado-trastuzumab-emtansine (TDM-1; 5 mg/kg weekly); trastuzumab (5 mg/kg once weekly) + lapatinib (100 mg/kg daily); or TDM-1 (5 mg/kg weekly) + lapatinib (100 mg/kg daily). Tumor volume fold-change will be measured twice weekly post treatment. (B), (C) BT474 and SKBR3 HER2-positive cell lines were treated with the following: vehicle control; TDM-1 (1 μg/ml); trastuzumab (10 μg/ml) + lapatinib (10 μM) 4); or TDM-1 (1 μg/ml) + lapatinib (10 μM). Cells were assessed for proliferation and apoptosis post treatment. *Data analyzed by one way analysis of variance followed by Tukey analysis for a pairwise comparison of different groups, P < 0.05. T, trastuzumab; L, lapatinib. Data from J Chang, unpublished data.


  1. Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014, 16: 419-10.1186/s13058-014-0419-5.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jenny C Chang.

Additional information

The online version of the original article can be found at 10.1186/s13058-014-0419-5

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Patel, T.A., Dave, B., Rodriguez, A.A. et al. Erratum to: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 16, 468 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: